Start Free Trial
Pricing
Log In
Log In
Upgrade browser for full Crunchbase experience. You're accessing Crunchbase in a browser that is no longer supported.
Learn More
NOVACYT Logo
NOVACYT Growth Score
12
CB Rank
101324
Heat Score
59
NOVACYT develops cellular diagnostics with a growing portfolio of cancer and infectious disease products and services.
Founded
obfuscation
PublicPost-IPO Debt Vélizy-villacoublay, Ile-de-France, France101-250 www.novacyt.com/
Biotechnology
Health Care
Health Diagnostics
Life Science
Professional Services
Overview

NOVACYT
Total Funding
obfuscation
Growth Score
12
Heat Score
59

Total Funding
obfuscation
obfuscation
Post-IPO Debt raised
obfuscation
Growth Score12
-7 pts
in past quarter
Heat Score 59
1 pts
in past quarter

Company Performance Metrics

Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Learn More >
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience

About NOVACYT

CB Rank
101324
NOVACYT develops cellular diagnostics with a growing portfolio of cancer and infectious disease products and services.
Founded
obfuscation
PublicPost-IPO Debt Vélizy-villacoublay, Ile-de-France, France101-250 www.novacyt.com/
Biotechnology
Health Care
Health Diagnostics
Life Science
Professional Services

Funding Rounds

Post-IPO Debt
OBF
in
obfuscation
Post-IPO Debt
OBF
in
obfuscation
Post-IPO Equity
OBF
in
obfuscation

Key People

Details

Legal Name Novacyt SA.
Operating Status Active
Stock Symbol  EPA:ALNOV
Company Type For Profit
Founders  Eric Peltier
About the Company

The Novacyt Group is a rapidly growing, international diagnostics business generating an increasing portfolio of in vitro and molecular diagnostic tests. Its core strengths lie in diagnostics product development, commercialisation, contract design and manufacturing. The Company’s lead business units comprise of Primerdesign and Lab21 Products,

supplying an extensive range of high quality assays and reagents worldwide. The Group directly serves oncology, microbiology, haematology and serology markets as do its global partners, which include major corporates.

Phone Number +330139465104
Contact Email info@novacyt.com
Predictions & Insights

Growth Insight

See this Growth Insight
NOVACYT is
Lorem
 to be growing
Top Contributing Factors
Merger or Acquisition

Products & Services

Non-Invasive Prenatal Testing (NIPT) - IONA® Care+
A prenatal screening test that detects genetic conditions including microdeletions using cell-free DNA analysis.
Ranger® Technology
An automated DNA sample preparation and target enrichment platform using computer vision for size selection.

Unlock More with Crunchbase Pro
  • Full access to financial & funding data on unlimited profiles
  • Export up to 2k results/month for analysis
  • Track market signals on competitors, products, and R&D
  • Preview private company insights and predictions
Financials

Company Funding

Total Funding Amount 
obfuscation
Number of Funding Rounds 8
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Post-IPO Debt - NOVACYT Logo
Post-IPO Debt - NOVACYT
1
obfuscation
— Post-IPO Debt
obfuscation
Post-IPO Debt - NOVACYT Logo
Post-IPO Debt - NOVACYT
1
obfuscation
— Post-IPO Debt
obfuscation
Post-IPO Debt - NOVACYT Logo
Post-IPO Debt - NOVACYT
1
obfuscation
— Post-IPO Debt
obfuscation
Post-IPO Debt - NOVACYT Logo
Post-IPO Debt - NOVACYT
1
obfuscation
— Post-IPO Debt
obfuscation
Post-IPO Debt - NOVACYT Logo
Post-IPO Debt - NOVACYT
1
obfuscation
— Post-IPO Debt

Funding Rounds

Total Funding Amount 
obfuscation
Number of Funding Rounds 8
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Post-IPO Debt - NOVACYT Logo
Post-IPO Debt - NOVACYT
1
obfuscation
— Post-IPO Debt
obfuscation
Post-IPO Debt - NOVACYT Logo
Post-IPO Debt - NOVACYT
1
obfuscation
— Post-IPO Debt
obfuscation
Post-IPO Debt - NOVACYT Logo
Post-IPO Debt - NOVACYT
1
obfuscation
— Post-IPO Debt
obfuscation
Post-IPO Debt - NOVACYT Logo
Post-IPO Debt - NOVACYT
1
obfuscation
— Post-IPO Debt
obfuscation
Post-IPO Debt - NOVACYT Logo
Post-IPO Debt - NOVACYT
1
obfuscation
— Post-IPO Debt

Investors

Unlock company funding data, including rounds, dates, amounts, and investors.
Investor Name  
Lead Investor  
Funding Round  
Partners  
Claret Capital Partners Logo
Claret Capital Partners
—
Post-IPO Debt - NOVACYT Logo
Post-IPO Debt - NOVACYT
—
Claret Capital Partners Logo
Claret Capital Partners
—
Post-IPO Debt - NOVACYT Logo
Post-IPO Debt - NOVACYT
—
Claret Capital Partners Logo
Claret Capital Partners
—
Post-IPO Debt - NOVACYT Logo
Post-IPO Debt - NOVACYT
—
Claret Capital Partners Logo
Claret Capital Partners
—
Post-IPO Debt - NOVACYT Logo
Post-IPO Debt - NOVACYT
—
Claret Capital Partners Logo
Claret Capital Partners
—
Post-IPO Debt - NOVACYT Logo
Post-IPO Debt - NOVACYT
—

Investments

Number of Acquisitions 6

Investment Breakdown

Number of Acquisitions 6
Market Intelligence
People
View Profiles & Contacts
Headcount 101-250 Employee Profiles 15 Contacts 32

Employee Profiles

News

News and Press

News•Jun 1, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Jun 1, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Apr 8, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Feb 23, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
Access a complete feed of recent news and press, from product launches to leadership changes.
Technology
View Tech Report

Monthly Web Visits

15,475
112.54%
 in past month

IT Spend

$1.4MThis year, NOVACYT is projected to spend $1.4M on IT, according to Aberdeen.

Actively Used Products

28NOVACYT uses 28 technology products and services including HTML5, Google Fonts, and  Google Maps API, according to G2 Stack.

Active Website Tech Count

49NOVACYT is actively using 49 technologies for its website, according to BuiltWith. These include IPhone / Mobile Compatible, SSL by Default, and  Viewport Meta.

Total IP

21The intellectual property of NOVACYT includes 20 registered patents primarily in the 'Testing' category, according to IPqwery. Additionally, NOVACYT has 1 registered trademark in the 'Chemical substances' class, according to IPqwery.
Sub-Organizations
Frequently Asked Questions

Where is NOVACYT's headquarters? NOVACYT is located in Vélizy-villacoublay, Ile-de-France, France.Who invested in NOVACYT? NOVACYT has 5 investors including Claret Capital Partners and  Kreos Capital.When was the last funding round for NOVACYT? NOVACYT closed its last funding round on
obfuscation
from a Post-IPO Debt round.Who are NOVACYT's competitors? Alternatives and possible competitors to NOVACYT may include Element Biosciences, Oxford Nanopore Technologies, and  seqWell.How much funding has NOVACYT raised to date? NOVACYT has raised
obfuscation
.
Who We Are
What We Do
Helpful Links
AI Content may contain mistakes and is not legal, financial or investment advice. Learn more.
Terms of Service | Privacy Policy | Sitemap | © 2026 Crunchbase Inc. All Rights Reserved.
(5eb04bf 1)
|